Skip Ribbon Commands
Skip to main content

​​​​​​​​​

​​​

Primary Diagnosis

Heart Failure

Study Purpose​

To test the safety and efficacy of Omecamtiv Mecarbil in patients with chronic heart failure with reduced ejection fraction.

Principal Investigator: David Rawitscher, MD

Trial Details

Locations: Legacy Heart Center Plano, Congestive Heart Failure Center Plano, The Heart Hospital Baylor Plano, The Heart Group Plano and The Heart Group McKinney

Sponsor: Amgen

IRB Number: 017-020

Trial Status: Enrolling

Exclusions: Adults only

Change in Care: Participating will ​change your care

Contact Information:

Alexandria Biberstein, RN
469.814.4732
Alexandria.Biberstein@BS​​WHealth.org

Full Protocol Title

A double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of Omecamtiv Mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction.

Get Detailed ​Infor​mation On Clinicaltrials.gov »​​​​​​​​​​​​​​​​​​​​

​​

​​

​​​​​​​​​​BAYLOR SCOTT & WHITE RESEARCH ​INSTITUTE​​